• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Evaluation of third nerve palsy remains problematic

Article

It's 4:55 p.m. on a Friday, last patient of the day-a 50-year-old man with diabetes and hypertension with new-onset right-sided ptosis and diplopia. Examination reveals a right third nerve palsy (TNP). What is the next most appropriate step?

Related Videos
Related Content
Ocugen completes dosing of subjects with geographic atrophy in Cohort 2 of Phase 1/2 ArMaDa clinical trial of OCU410

Ocugen completes dosing of subjects with geographic atrophy in Cohort 2 of Phase 1/2 ArMaDa clinical trial of OCU410

Article
Ehsan Sadri, MD, leads an ophthalmology innovation discussion with Jeffry Weinhuff of Visionary Ventures

(EyePod) From idea to impact: Navigating ophthalmic innovation

Podcast
Intracortical Visual Prosthesis achieves 2 years of successful testing

Intracortical Visual Prosthesis achieves 2 years of successful testing

Article
EyePod: Modifier Gene Therapy: What is it?

EyePod: Modifier Gene Therapy: What is it?

Podcast
Using extracellular vesicles in the treatment of ocular diseases

Using extracellular vesicles in the treatment of ocular diseases

Article
Ocular Therapeutix announces positive topline Phase 1 data for Axpaxli in diabetic retinopathy

Ocular Therapeutix announces positive topline Phase 1 data for Axpaxli in diabetic retinopathy

Article
© 2024 MJH Life Sciences

All rights reserved.